HBV Infection Status and the Risk of Cholangiocarcinoma in Asia: A Meta-Analysis

Abstract EN

Background.

The inconsistent finding was between hepatitis B virus (HBV) infections and cholangiocarcinoma (CCA).

This meta-analysis is to explore this relationship in Asia.

Methods.

A literature search was performed using PubMed, Web of Science, and Cochrane Library to October 30, 2015.

Pooled incidence rate and OR with 95% CI were calculated using STATA 11.0.

Results.

Thirty-nine studies were included.

The pooled incidence rate of CCA patients with HBV infection was 31% (95% CI 22%–39%).

The pooled OR showed increased risk of CCA incidence with HBV infection (OR = 2.72, 95% CI 1.90–3.88), especially in ICC (OR = 3.184, 95% CI 2.356–4.302), while it showed no risk in ECC (OR = 1.407, 95% CI 0.925–2.141).

Also, the pooled OR showed increased risk of ICC and ECC incidence (OR = 6.857, 95% CI 4.421–10.633 and OR = 1.740, 95% CI 1.260–2.404) in patients with HBsAg+/HBcAb+.

The pooled OR showed increased risk of ICC incidence (OR = 1.410, 95% CI 1.095–1.816) in patients with HBsAg−/HBcAb+.

Conclusion.

It is suggested that HBV infection is associated with an increased risk of CCA in Asia.

Two HBV infection models (HBsAg+/HBcAb+ and HBsAg−/HBcAb+) increase the risk of CCA, and patients with HBsAg−/HBcAb+ also had a risk of ICC.

This trial is registered with PROSPERO CRD42015029264.